.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The DEXA-ARDS trial evaluated a structured course of dexamethasone in adults with moderate-to-severe ARDS. Patients were randomised to intravenous dexamethasone or standard treatment, with the main goals of assessing ventilator-free days and survival. The corticosteroid group had more ventilator-free days and lower 60-day mortality, suggesting that appropriately timed anti-inflammatory therapy may improve outcomes in selected patients with established ARDS. The study is clinically relevant because corticosteroid use in ARDS has historically produced mixed results depending on timing, dose and patient selection. DEXA-ARDS provides evidence for a relatively early, prolonged steroid regimen rather than short rescue courses. For practice, however, the findings should be interpreted in the context of the broader evidence base and individual contraindications. Steroids can affect glucose control, muscle strength and infection risk, and ARDS is a heterogeneous syndrome with multiple causes. The trial does not support indiscriminate steroid use in every patient with acute lung injury. Instead, it strengthens the rationale for considering corticosteroids when the clinical phenotype and timing are appropriate. DEXA-ARDS also fits the broader movement toward phenotype-guided ARDS treatment rather than treating all patients with severe hypoxaemia as biologically identical.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The DEXA-ARDS trial evaluated a structured course of dexamethasone in adults with moderate-to-severe ARDS. Patients were randomised to intravenous dexamethasone or standard treatment, with the main goals of assessing ventilator-free days and survival. The corticosteroid group had more ventilator-free days and lower 60-day mortality, suggesting that appropriately timed anti-inflammatory therapy may improve outcomes in selected patients with established ARDS. The study is clinically relevant because corticosteroid use in ARDS has historically produced mixed results depending on timing, dose and patient selection. DEXA-ARDS provides evidence for a relatively early, prolonged steroid regimen rather than short rescue courses. For practice, however, the findings should be interpreted in the context of the broader evidence base and individual contraindications. Steroids can affect glucose control, muscle strength and infection risk, and ARDS is a heterogeneous syndrome with multiple causes. The trial does not support indiscriminate steroid use in every patient with acute lung injury. Instead, it strengthens the rationale for considering corticosteroids when the clinical phenotype and timing are appropriate. DEXA-ARDS also fits the broader movement toward phenotype-guided ARDS treatment rather than treating all patients with severe hypoxaemia as biologically identical.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
